Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
about
Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design.Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.A multistep docking and scoring protocol for congeneric series: Implementation on kinase DFG-out type II inhibitors.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib.
P2860
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
@en
type
label
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
@en
prefLabel
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
@en
P2093
P2860
P50
P1476
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
@en
P2093
Carminia Maria Della Corte
Erika Martinelli
Morena Fasano
P2860
P304
P356
10.1517/13543784.2014.902934
P407
P577
2014-03-28T00:00:00Z